Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study is being done to test the safety and effectiveness of pembrolizumab followed by
radiation therapy in Hodgkin lymphoma.
The purpose of this study is to determine how effective combining the research drug,
pembrolizumab, with a targeted form of radiation therapy known as involved site radiotherapy
can be in patients with relapsed or refractory early stage classical Hodgkin lymphoma. The
goal is to see whether this treatment strategy can cure a significant number of patients with
relapsed or refractory early stage classical Hodgkin lymphoma while avoiding the toxicity of
either a large radiation field or further chemotherapy and stem cell transplant.